Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer - European Medical Journal

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumour expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given